NASDAQ:SAGE - Sage Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $86.69
  • Forecasted Upside: 15.51 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$75.05
▲ +0.41 (0.55%)
1 month | 3 months | 12 months
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$86.69
▲ +15.51% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $86.69, with a high forecast of $135.00 and a low forecast of $35.00. The average price target represents a 15.51% upside from the last price of $75.05.
Buy
The current consensus among 16 polled investment analysts is to buy stock in Sage Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 9 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Morgan StanleyLower Price TargetEqual Weight$87.00 ➝ $81.00Low
i
4/12/2021MizuhoReiterated RatingHold$81.00High
i
4/7/2021Piper SandlerInitiated CoverageOverweight$100.00Medium
i
3/8/2021Morgan StanleyBoost Price TargetEqual Weight$83.00 ➝ $87.00N/A
i
3/4/2021MizuhoReiterated RatingBuy ➝ Neutral$81.00High
i
3/3/2021OppenheimerBoost Price TargetOutperform$90.00 ➝ $102.00High
i
3/2/2021Morgan StanleyBoost Price TargetEqual Weight$83.00 ➝ $87.00High
i
2/26/2021MizuhoDowngradeBuy ➝ Neutral$81.00High
i
2/25/2021OppenheimerBoost Price TargetOutperform$90.00 ➝ $102.00Low
i
2/25/2021HC WainwrightBoost Price TargetNeutral$74.00 ➝ $86.00High
i
Rating by D. Tsao at HC Wainwright
2/25/2021HC WainwrightReiterated RatingNeutral$74.00 ➝ $86.00High
i
Rating by D. Tsao at HC Wainwright
2/1/2021Raymond JamesInitiated CoverageMarket PerformLow
i
Rating by Dane Leone at Raymond James
1/22/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$95.00High
i
1/19/2021WedbushBoost Price TargetOutperform$83.00 ➝ $98.00Low
i
Rating by L. Chico at Wedbush
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
i
1/4/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$83.00 ➝ $86.00N/A
i
12/4/2020William BlairReiterated RatingBuyLow
i
12/4/2020MizuhoUpgradeNeutral ➝ Buy$77.00 ➝ $81.00Low
i
12/1/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$100.00 ➝ $93.00Low
i
12/1/2020TruistBoost Price Target$60.00 ➝ $70.00Low
i
12/1/2020Smith Barney CitigroupLower Price Target$100.00 ➝ $93.00Low
i
12/1/2020Royal Bank of CanadaLower Price Target$86.00 ➝ $83.00Low
i
12/1/2020HC WainwrightLower Price TargetNeutral$81.00 ➝ $74.00Low
i
Rating by D. Tsao at HC Wainwright
12/1/2020Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $83.00Low
i
11/30/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
Rating by Dane Leone at Raymond James
11/19/2020OppenheimerBoost Price Target$65.00 ➝ $94.00Medium
i
11/16/2020Bank of AmericaBoost Price TargetBuy$72.00 ➝ $95.00High
i
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$87.00 ➝ $85.00High
i
11/10/2020TruistBoost Price TargetHold$35.00 ➝ $60.00Low
i
11/6/2020Smith Barney CitigroupBoost Price Target$67.00 ➝ $100.00Low
i
11/6/2020Canaccord GenuityBoost Price TargetBuy$82.00 ➝ $135.00Low
i
11/6/2020MizuhoBoost Price TargetNeutral$53.00 ➝ $77.00Medium
i
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$79.00 ➝ $89.00Medium
i
11/6/2020HC WainwrightBoost Price TargetNeutral$76.00 ➝ $81.00Medium
i
Rating by D. Tsao at HC Wainwright
10/20/2020Royal Bank of CanadaBoost Price TargetOutperform$75.00 ➝ $84.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
10/16/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$65.00 ➝ $79.00High
i
9/11/2020CitigroupBoost Price TargetPositive ➝ Buy$54.00 ➝ $67.00Low
i
9/11/2020WedbushUpgradeNeutral ➝ Outperform$40.00 ➝ $65.00Low
i
Rating by L. Chico at Wedbush
8/24/2020Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $87.00Medium
i
8/11/2020Royal Bank of CanadaReiterated RatingBuyMedium
i
Rating by Brian Abrahams at Royal Bank of Canada
8/11/2020OppenheimerBoost Price TargetOutperform$50.00 ➝ $65.00High
i
8/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00Low
i
8/10/2020MizuhoReiterated RatingHold$44.00High
i
5/26/2020Royal Bank of CanadaBoost Price TargetOutperform$72.00 ➝ $75.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020SunTrust BanksLower Price TargetHold$37.00 ➝ $35.00High
i
5/8/2020Royal Bank of CanadaBoost Price TargetOutperform$71.00 ➝ $72.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $37.00Medium
i
Rating by L. Chico at Wedbush
5/8/2020MizuhoBoost Price TargetNeutral$36.00 ➝ $44.00Medium
i
Rating by Vamil Divan at Mizuho
4/28/2020Royal Bank of CanadaBoost Price TargetOutperform$68.00 ➝ $71.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
4/19/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
4/9/2020BMO Capital MarketsLower Price TargetOutperform$86.00 ➝ $65.00Medium
i
4/9/2020SunTrust BanksLower Price TargetHold$40.00 ➝ $37.00Medium
i
4/8/2020Canaccord GenuityLower Price TargetBuy$96.00 ➝ $80.00Low
i
4/8/2020Royal Bank of CanadaBoost Price TargetOutperform$60.00 ➝ $68.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
4/8/2020WedbushLower Price TargetOutperform$56.00 ➝ $36.00High
i
4/8/2020OppenheimerLower Price TargetOutperform$60.00 ➝ $50.00High
i
4/8/2020CitigroupBoost Price TargetBuy$48.00 ➝ $54.00High
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
4/8/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
4/8/2020MizuhoLower Price TargetNeutral$58.00 ➝ $36.00High
i
Rating by Vamil Divan at Mizuho
3/26/2020SunTrust BanksLower Price TargetHold$50.00 ➝ $40.00Medium
i
3/22/2020HC WainwrightReiterated RatingHold$78.00Low
i
Rating by Douglas Tsao at HC Wainwright
3/20/2020LADENBURG THALM/SH SHReiterated RatingHold$28.00High
i
3/19/2020OppenheimerLower Price Target$97.00 ➝ $60.00Low
i
3/19/2020SVB LeerinkBoost Price TargetMarket Perform$45.00 ➝ $63.00Low
i
Rating by Marc Goodman at SVB Leerink LLC
3/19/2020GuggenheimLower Price TargetBuy$85.00 ➝ $65.00Low
i
3/19/2020CitigroupLower Price TargetBuy$71.00 ➝ $48.00Low
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
3/18/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$73.00 ➝ $60.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
3/11/2020MizuhoReiterated RatingHold$58.00High
i
Rating by Vamil Divan at Mizuho
3/5/2020CitigroupInitiated CoverageBuy$71.00High
i
3/3/2020Morgan StanleyLower Price TargetOverweight$125.00 ➝ $117.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
2/28/2020SunTrust BanksLower Price TargetHold$60.00 ➝ $50.00High
i
2/28/2020LADENBURG THALM/SH SHReiterated RatingHold$52.00High
i
2/28/2020HC WainwrightLower Price TargetNeutral$87.00 ➝ $78.00High
i
Rating by Douglas Tsao at HC Wainwright
2/28/2020MizuhoLower Price TargetNeutral$69.00 ➝ $58.00High
i
Rating by Vamil Divan at Mizuho
2/27/2020CowenReiterated RatingBuy$96.00High
i
2/27/2020MizuhoReiterated RatingHold$69.00High
i
Rating by Vamil Divan at Mizuho
2/5/2020MizuhoInitiated CoverageNeutral$69.00Low
i
1/7/2020Bank of AmericaBoost Price Target$85.00 ➝ $98.00Medium
i
12/6/2019OppenheimerLower Price Target$190.00 ➝ $100.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/6/2019JPMorgan Chase & Co.Lower Price TargetOverweight$200.00 ➝ $105.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/6/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
i
12/6/2019Royal Bank of CanadaLower Price TargetOutperform$190.00 ➝ $100.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
12/6/2019Morgan StanleyLower Price TargetOverweight$217.00 ➝ $125.00High
i
12/6/2019BMO Capital MarketsReiterated RatingOutperform$92.00High
i
12/6/2019SVB LeerinkUpgradeUnderperform ➝ Market PerformHigh
i
Rating by M. Goodman at SVB Leerink LLC
12/6/2019HC WainwrightLower Price TargetNeutral$160.00 ➝ $87.00High
i
Rating by D. Tsao at HC Wainwright
12/5/2019The Goldman Sachs GroupLower Price Target$227.00 ➝ $263.00High
i
12/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$206.00 ➝ $125.00High
i
12/5/2019GuggenheimLower Price TargetBuy$200.00 ➝ $110.00High
i
12/5/2019CowenReiterated RatingBuy$96.00High
i
12/5/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$73.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
12/5/2019WedbushLower Price TargetOutperform$203.00 ➝ $90.00High
i
12/5/2019SunTrust BanksDowngradeBuy ➝ Hold$210.00 ➝ $70.00High
i
11/25/2019Royal Bank of CanadaReiterated RatingBuy$235.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
11/24/2019Morgan StanleyReiterated RatingBuy$217.00Medium
i
11/20/2019Stifel NicolausReiterated RatingBuyLow
i
Rating by Paul Matteis at Stifel Nicolaus
10/30/2019HC WainwrightInitiated CoverageNeutral$160.00Low
i
Rating by D. Tsao at HC Wainwright
8/7/2019OppenheimerLower Price TargetOutperform$200.00 ➝ $190.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/25/2019OppenheimerBoost Price Target$170.00 ➝ $200.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/24/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/24/2019William BlairReiterated RatingBuyLow
i
Rating by Tim Lugo at William Blair
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$207.00Low
i
Rating by L. Chico at Wedbush
5/5/2019OppenheimerSet Price TargetBuy$170.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/2/2019LADENBURG THALM/SH SHSet Price TargetBuy$220.00Low
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
4/26/2019Raymond JamesReiterated RatingMarket PerformMedium
i
4/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$195.00Low
i
4/8/2019Canaccord GenuitySet Price TargetBuy$220.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
2/22/2019GuggenheimInitiated CoverageBuy$205.00High
i
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$230.00 ➝ $213.00High
i
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
i
12/11/2018LADENBURG THALM/SH SHSet Price TargetBuy$210.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
11/20/2018OppenheimerSet Price TargetBuy$170.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/12/2018SVB LeerinkInitiated CoverageUnderperform$80.00High
i
Rating by M. Goodman at SVB Leerink LLC
11/6/2018JPMorgan Chase & Co.Set Price TargetBuy$205.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$259.00 ➝ $261.00Medium
i
11/4/2018OppenheimerSet Price TargetBuy$170.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/1/2018Canaccord GenuitySet Price TargetBuy$220.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
11/1/2018CowenReiterated RatingBuy$207.00High
i
10/31/2018LADENBURG THALM/SH SHSet Price TargetBuy$235.00High
i
Rating by Michael Higgins at LADENBURG THALM/SH SH
10/29/2018OppenheimerSet Price TargetBuy$170.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2018OppenheimerInitiated CoverageBuy$170.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/11/2018Morgan StanleyBoost Price TargetOverweight$228.00 ➝ $230.00High
i
10/10/2018OppenheimerInitiated CoverageBuy$170.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018Canaccord GenuitySet Price TargetBuy$220.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
8/7/2018Stifel NicolausBoost Price TargetBuy$198.00 ➝ $239.00Medium
i
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$206.00Medium
i
7/13/2018Morgan StanleyBoost Price TargetOverweight$225.00 ➝ $228.00Low
i
6/14/2018CowenReiterated RatingBuy$207.00Medium
i
6/12/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$220.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$230.00High
i
5/3/2018Canaccord GenuityReiterated RatingBuy$210.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
5/3/2018CowenReiterated RatingBuyLow
i
3/26/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$210.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
3/20/2018CowenReiterated RatingBuy$202.00Low
i
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00Low
i
Rating by Edward Nash at SunTrust Banks, Inc.
2/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$225.00Low
i
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00Low
i
Rating by Danielle Brill at Needham & Company LLC
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
12/11/2017CowenReiterated RatingBuyLow
i
12/8/2017Stifel NicolausReiterated RatingBuy$198.00Low
i
Rating by Keith Gay at Stifel Nicolaus
12/8/2017SunTrust BanksBoost Price TargetPositive$178.00High
i
Rating by Edward Nash at SunTrust Banks, Inc.
12/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight$198.00High
i
12/7/2017Raymond JamesReiterated RatingBuy$206.00High
i
Rating by Laura Chico at Raymond James
12/7/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$140.00 ➝ $191.00High
i
Rating by John Newman at Canaccord Genuity
12/7/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$100.00 ➝ $193.00High
i
Rating by Danielle Brill at Needham & Company LLC
12/7/2017SVB LeerinkBoost Price Target$123.00 ➝ $246.00High
i
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00High
i
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Sell$137.00 ➝ $280.00High
i
11/27/2017Royal Bank of CanadaLower Price TargetOutperform$145.00 ➝ $137.00Medium
i
11/17/2017BMO Capital MarketsReiterated RatingOutperform$85.67 ➝ $112.00N/A
i
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $101.00N/A
i
11/15/2017SunTrust BanksBoost Price TargetBuy ➝ Positive$116.00N/A
i
Rating by Edward Nash at SunTrust Banks, Inc.
11/10/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$86.00 ➝ $100.00N/A
i
Rating by Danielle Brill at Needham & Company LLC
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/A
i
Rating by G. Amusa at Chardan Capital
11/9/2017Raymond JamesBoost Price TargetBuy$109.00N/A
i
11/9/2017Stifel NicolausBoost Price TargetBuy$91.00 ➝ $105.00N/A
i
Rating by Keith Gay at Stifel Nicolaus
11/9/2017Royal Bank of CanadaBoost Price TargetOutperform$145.00N/A
i
11/9/2017SVB LeerinkBoost Price TargetOutperform ➝ Positive$85.00 ➝ $123.00N/A
i
11/2/2017Royal Bank of CanadaBoost Price Target$117.00 ➝ $120.00N/A
i
10/27/2017BMO Capital MarketsReiterated RatingBuy$80.00N/A
i
10/19/2017SunTrust BanksSet Price TargetBuy$82.00N/A
i
Rating by Edward Nash at SunTrust Banks, Inc.
10/18/2017Royal Bank of CanadaReiterated RatingBuy$117.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$87.00N/A
i
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$117.00Medium
i
9/14/2017BMO Capital MarketsBoost Price TargetOutperform$80.00 ➝ $84.00High
i
9/13/2017Chardan CapitalReiterated RatingHoldHigh
i
9/13/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$95.00 ➝ $86.00High
i
Rating by Danielle Brill at Needham & Company LLC
9/13/2017Stifel NicolausReiterated RatingBuy$104.00 ➝ $91.00High
i
Rating by Keith Gay at Stifel Nicolaus
9/13/2017SunTrust BanksReiterated RatingBuy$95.00 ➝ $82.00High
i
9/12/2017Canaccord GenuityLower Price TargetBuy$110.00 ➝ $81.00High
i
Rating by John Newman at Canaccord Genuity
9/12/2017JPMorgan Chase & Co.Lower Price TargetOverweight$99.00 ➝ $85.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/12/2017CowenLower Price TargetOutperform$100.00 ➝ $90.00Medium
i
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017Stifel NicolausInitiated CoverageBuy$104.00Low
i
8/5/2017Canaccord GenuitySet Price TargetBuy$110.00Medium
i
Rating by John Newman at Canaccord Genuity
8/4/2017CowenReiterated RatingBuy$100.00Medium
i
8/4/2017Needham & Company LLCSet Price TargetBuy$82.00 ➝ $95.00High
i
Rating by Danielle Brill at Needham & Company LLC
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00High
i
Rating by C. Werther at HC Wainwright
7/28/2017BMO Capital MarketsReiterated RatingBuy$82.00Medium
i
Rating by Gary Nachman at BMO Capital Markets
7/14/2017Stifel NicolausReiterated RatingBuy$90.00Medium
i
6/20/2017SVB LeerinkReiterated RatingOutperform$90.00 ➝ $97.00High
i
6/13/2017Needham & Company LLCReiterated RatingBuy$82.00Medium
i
6/12/2017CowenInitiated CoverageOutperform$95.00Low
i
5/15/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$82.00Low
i
5/12/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$85.00High
i
5/10/2017Canaccord GenuityReiterated RatingBuy$110.00Medium
i
Rating by John Newman at Canaccord Genuity
4/12/2017Canaccord GenuitySet Price TargetBuy$110.00High
i
Rating by John Newman at Canaccord Genuity
4/3/2017JPMorgan Chase & Co.Reiterated RatingBuy$83.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/21/2017Canaccord GenuityReiterated RatingBuy$110.00High
i
Rating by John Newman at Canaccord Genuity
3/6/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
2/23/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
2/22/2017HC WainwrightDowngradeBuy ➝ Neutral$56.00 ➝ $76.00N/A
i
Rating by C. Werther at HC Wainwright
2/22/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $82.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
2/14/2017Chardan CapitalUpgradeSell ➝ Neutral$60.00N/A
i
2/13/2017CowenReiterated RatingBuy$95.00N/A
i
2/13/2017BMO Capital MarketsSet Price TargetOutperform ➝ Buy$68.00N/A
i
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/15/2016JPMorgan Chase & Co.Reiterated RatingBuy$74.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/14/2016Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
12/14/2016Raymond JamesUpgradeOutperform ➝ Strong-Buy$84.00N/A
i
12/14/2016UBS GroupUpgradeOutperform ➝ Strong-BuyN/A
i
12/6/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by john newman at Canaccord Genuity
11/14/2016Stifel NicolausInitiated CoverageBuy$90.00N/A
i
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
10/4/2016SVB LeerinkReiterated RatingOutperform$68.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
9/19/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
9/13/2016Raymond JamesInitiated CoverageOutperform$75.00N/A
i
9/6/2016Canaccord GenuitySet Price TargetBuy$110.00N/A
i
Rating by john newman at Canaccord Genuity
8/12/2016BMO Capital MarketsReiterated RatingBuy$57.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
7/15/2016William BlairReiterated RatingOutperform$75.00N/A
i
Rating by Tim Lugo at William Blair
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/12/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
7/12/2016Chardan CapitalReiterated RatingSellN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
7/12/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Gary Nachman at BMO Capital Markets
7/12/2016SVB LeerinkReiterated RatingBuy$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$48.00N/A
i
6/23/2016HC WainwrightInitiated CoverageBuy$56.00N/A
i
Rating by C. Werther at HC Wainwright
6/21/2016SVB LeerinkReiterated RatingOutperform$66.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/8/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
6/8/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
6/8/2016Chardan CapitalReiterated RatingSellN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
5/27/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/24/2016Chardan CapitalInitiated CoverageSell$18.00N/A
i
5/16/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/14/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
5/13/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
5/8/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
i
Rating by John Newman at Canaccord Genuity
(Data available from 4/19/2016 forward)
Sage Therapeutics logo
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $75.05
$73.15
$77.21

50 Day Range

MA: $77.11
$70.65
$87.28

52 Week Range

Now: $75.05
$30.33
$98.39

Volume

398,849 shs

Average Volume

494,140 shs

Market Capitalization

$4.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Bank of America Co., BMO Capital Markets, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, SunTrust Banks, Inc., TheStreet, Truist, Wedbush, and William Blair.
View the latest analyst ratings for SAGE.

What is the current price target for Sage Therapeutics?

16 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $87.06, suggesting a possible upside of 16.6%. Canaccord Genuity has the highest price target set, predicting SAGE will reach $135.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $35.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 8 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SAGE will outperform the market and that investors should add to their positions of Sage Therapeutics.
View the latest ratings for SAGE.

What other companies compete with Sage Therapeutics?

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-299-8380 and its investor relations email address is [email protected] The official website for Sage Therapeutics is www.sagerx.com.